Lyka Labs Limited has reported a standalone net loss of ₹322.88 crore for the financial year ended March 31, 2026, a reversal from the net profit of ₹79.18 crore recorded in the previous fiscal year. The consolidated financial results for the year also reflected a net loss of ₹104.36 crore. The decline was primarily driven by the recognition of an exceptional impairment loss amounting to ₹230.14 crore regarding its investment and loans in subsidiary Lyka BDR International Limited. The Board of Directors approved the audited financial results during a meeting held on May 25, 2026.

Financial Performance for FY26

Standalone revenue from operations for the year decreased to ₹120.90 crore from ₹134.69 crore in the prior year. Total income for FY26 stood at ₹124.87 crore, compared to ₹137.45 crore in FY25. Total expenses rose to ₹135.10 crore from ₹126.35 crore year-on-year. The company reported a profit before exceptional items and tax of ₹(10.22) crore, compared to ₹11.10 crore in the previous year. On a consolidated basis, total income from operations was ₹131.94 crore.

Exceptional Impairment Charge

A key factor impacting the financials was the recognition of an impairment loss amounting to ₹230.14 crore. This charge relates to the company's investment and loans in its subsidiary, Lyka BDR International Limited. The impairment was necessitated by continuous operational losses and the severe erosion of the subsidiary's net worth. Consequently, the carrying value of these investments and loans has been reduced to Nil.

Quarterly Results

For the quarter ended March 31, 2026, the company reported a standalone net loss of ₹29.77 crore. Revenue from operations for the quarter was ₹28.54 crore, while total expenses stood at ₹35.43 crore. The exceptional item of ₹230.14 crore was recorded during this quarter, significantly affecting the bottom line. On a consolidated basis, the net loss for the quarter was ₹8.07 crore.

Corporate Actions

The Board has fixed June 4, 2026, as the record date to determine shareholders eligible to receive equity shares pursuant to the Scheme of Amalgamation with Lyka Exports Limited. Shareholders will receive 23 fully paid-up equity shares of ₹10 each for every 100 shares held. The 47th Annual General Meeting is scheduled for August 10, 2026.

Key Financial Metrics

The following table outlines the standalone and consolidated financial performance for the year ended March 31, 2026:

M/s. D. Kothary & Co., Statutory Auditors, have issued an unmodified opinion on the audited financial results.

Lyka Labs Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Monday, May 25, 2026. The intimation was issued pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and communicated to both BSE Limited and the National Stock Exchange of India Limited on May 12, 2026.

Board Meeting Agenda

The board meeting has been convened to consider and approve key financial disclosures. The following items are on the agenda:

• Audited Standalone and Consolidated financial results of the Company for the quarter and financial year ended March 31, 2026
• Any other businesses

Meeting Details at a Glance

The key details of the scheduled board meeting are summarised below:

Regulatory Compliance

The intimation has been filed in compliance with SEBI's listing obligations framework, which mandates advance disclosure of board meetings where financial results are to be considered. Lyka Labs has also made this information available on its official website at www.lykalabs.com , in line with applicable disclosure requirements.